| Title |
Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2013
|
| DOI | 10.1007/s10549-013-2712-x |
| Pubmed ID | |
| Authors |
S. Wassertheil-Smoller, A. P. McGinn, N. Budrys, R. Chlebowski, G. Y. Ho, K. C. Johnson, D. S. Lane, W. Li, M. L. Neuhouser, J. Saquib, J. M. Shikany, Y. Song, C. Thomson |
| Abstract |
Multivitamin use is common in the United States. It is not known whether multivitamins with minerals supplements (MVM) used by women already diagnosed with invasive breast cancer would affect their breast cancer mortality risk. To determine prospectively the effects of MVM use on breast cancer mortality in postmenopausal women diagnosed with invasive breast cancer, a prospective cohort study was conducted of 7,728 women aged 50-79 at enrollment in the women's health initiative (WHI) in 40 clinical sites across the United States diagnosed with incident invasive breast cancer during WHI and followed for a mean of 7.1 years after breast cancer diagnosis. Use of MVM supplements was assessed at WHI baseline visit and at visit closest to breast cancer diagnosis, obtained from vitamin pill bottles brought to clinic visit. Outcome was breast cancer mortality. Hazard ratios and 95 % confidence intervals (CIs) for breast cancer mortality comparing MVM users to non-users were estimated using Cox proportional hazard regression models. Analyses using propensity to take MVM were done to adjust for potential differences in characteristics of MVM users versus non-users. At baseline, 37.8 % of women reported MVM use. After mean post-diagnosis follow-up of 7.1 ± 4.1 (SD) years, there were 518 (6.7 %) deaths from breast cancer. In adjusted analyses, breast cancer mortality was 30 % lower in MVM users as compared to non-users (HR = 0.70; 95 % CI 0.55, 0.91). This association was highly robust and persisted after multiple adjustments for potential confounding variables and in propensity score matched analysis (HR = 0.76; 95 % CI 0.60-0.96). Postmenopausal women with invasive breast cancer using MVM had lower breast cancer mortality than non-users. The results suggest a possible role for daily MVM use in attenuating breast cancer mortality in women with invasive breast cancer but the findings require confirmation. |
X Demographics
The data shown below were collected from the profiles of 37 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 11 | 30% |
| Canada | 3 | 8% |
| United Kingdom | 2 | 5% |
| Netherlands | 1 | 3% |
| Seychelles | 1 | 3% |
| Australia | 1 | 3% |
| France | 1 | 3% |
| Japan | 1 | 3% |
| Germany | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 14 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 30 | 81% |
| Practitioners (doctors, other healthcare professionals) | 7 | 19% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Lebanon | 1 | 2% |
| United States | 1 | 2% |
| Canada | 1 | 2% |
| Unknown | 48 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Student > Bachelor | 6 | 12% |
| Student > Master | 5 | 10% |
| Other | 3 | 6% |
| Lecturer | 2 | 4% |
| Other | 7 | 14% |
| Unknown | 19 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 22% |
| Agricultural and Biological Sciences | 7 | 14% |
| Nursing and Health Professions | 5 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Social Sciences | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 21 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 169. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2022.
All research outputs
#230,997
of 24,833,726 outputs
Outputs from Breast Cancer Research and Treatment
#27
of 4,921 outputs
Outputs of similar age
#1,675
of 216,069 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#3
of 66 outputs
Altmetric has tracked 24,833,726 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,921 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.